SCHEMBL23870286

SCHEMBL23870286

CC(C)C(CCC(N)=O)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
KMT2A Q03164 1/20 0.43
ECE1 P42892 3/20 0.39
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
GABRP O00591 2/20 0.34
GABRD O14764 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRB1 P18505 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28131067 0.85 LTA4H (0.40) ALOX15BLMPMP22KMT2AECE1
SCHEMBL3467869 0.85 LTA4H (0.40) ALOX15BLMPMP22KMT2AECE1
SCHEMBL15592482 0.84 GABRP (0.54) BLMPMP22KMT2AECE1SLC1A3
SCHEMBL25766149 0.84 GABRP (0.54) BLMPMP22KMT2AECE1SLC1A3
SCHEMBL23870285 0.84 GABRP (0.54) BLMPMP22KMT2AECE1SLC1A3
SCHEMBL5892037 0.84 ALOX15 (0.46) ALOX15BLMPMP22KMT2AECE1
SCHEMBL10037179 0.84 ALOX15 (0.52) ALOX15BLMPMP22KMT2AECE1
SCHEMBL14803503 0.84 ALOX15 (0.52) ALOX15BLMPMP22KMT2AECE1
SCHEMBL20713616 0.79 ECE1 (0.42) ALOX15BLMPMP22KMT2AECE1
SCHEMBL6205731 0.78 CA1 (0.41) ECE1SLC1A3SLC1A2SLC1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021195183-A1 COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE EXO THERAPEUTICS, INC. (US) 2021-09-30 WO disclosed